as 12-20-2024 4:00pm EST
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Founded: | 2011 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 25.1M | IPO Year: | N/A |
Target Price: | $4.00 | AVG Volume (30 days): | 169.0K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.88 | EPS Growth: | N/A |
52 Week Low/High: | $0.65 - $2.60 | Next Earning Date: | 11-07-2024 |
Revenue: | $23,052,000 | Revenue Growth: | -2.09% |
Revenue Growth (this year): | 34.56% | Revenue Growth (next year): | 39.35% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Nelson Steven Charles | DRIO | Chief Commercial Officer | Nov 12 '24 | Buy | $0.91 | 5,000 | $4,546.00 | 55,000 |
DRIO Breaking Stock News: Dive into DRIO Ticker-Specific Updates for Smart Investing
Argus Research
a month ago
Argus Research
a month ago
Argus Research
a month ago
Argus Research
a month ago
PR Newswire
a month ago
Argus Research
a month ago
Argus Research
a month ago
Argus Research
a month ago
The information presented on this page, "DRIO DarioHealth Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.